European Psychiatry - Volume 41 - April 2017

323 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S303–S364 S319
5 Università degli Studi di Modena e Reggio Emilia, Dipartimento di
Scienze Biomediche- Metaboliche e Neuroscienze, Modena, Italy
∗ Corresponding author.
Introduction Metabolic syndrome (MetS) is defined by metabo-
lic and cardio-vascular impairments and is frequently associated
with anxiety and depressive disorders. Both MetS and anxiety-
depressive syndromes feature similar systemic inflammatory
alterations. Inflammation of the large bowel is also a key factor
for the development of colorectal cancer (CRC).
Objective To measure the prevalence of MetS and symptoms of
anxiety and depression among patients undergoing colonoscopy.
Methods Cross-sectional study. Patients undergoing colonoscopy
aged 40 or more, with negative history for neoplasia or inflam-
matory bowel disease, were enrolled. Data collected: colonoscopy
outcome, presence/absence of MetS (IDF and ATP III criteria), pre-
sence/absence of depressive and anxiety symptoms assessed with
HADS.
Results The sample was made up of 53 patients (female 24,
45.3%). Mean agewas 60.66 ± 9.08. At least one adenomawas found
to 23 patients (43.3%). Prevalence of MetS ranged from 34% to 36%
(ATP III and IDF criteria, respectively). Prevalence of depressive and
anxiety symptoms was 20% and 33%, respectively.
Conclusion Prevalence of MetS, anxiety and depressive symp-
toms among patients undergoing colonoscopy was higher than in
the general population.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0623
Impact of anxiety-depressive
symptoms on outpatients’ quality of
life: Preliminary results from an
Italian observational study
S. Tassi , G. Rioli ∗, G. Mattei , S. Ferrari , G.M. Galeazzi
1 Università degli studi di modena e Reggio Emilia, Corso di Laurea in
Medicina e Chirurgia, Modena, Italy
2 Università degli Studi di Modena e Reggio Emilia, Scuola di
Specializzazione in Psichiatria, Sassuolo, Italy
3 Università degli Studi di Modena e Reggio Emilia, Scuola di
Specializzazione in Psichiatria, Modena, Italy
4 Università degli Studi di Modena e Reggio Emilia, Dipartimento di
Medicina Diagnostica- Clinica e di Sanità Pubblica- sezione di
Psichiatria, Modena, Italy
∗ Corresponding author.
Introduction Several studies have shown an association between
the Short-Form36 (SF36) scores and anxiety-depressive symptoms,
suggesting that depression in particular could reduce Quality of
Life (QoL) to the same, and even greater, extent than chronic non-
communicable diseases, such as diabetes and hypertension.
Aims To explore the relationship amongQoL and anxiety, depres-
sive and anxiety-depressive symptoms in an outpatient sample.
Methods Cross-sectional study. Inclusion criteria: outpatients
aged ≥40 years, without history for cancer, attending colono-
scopy after positive faecal occult blood test. Collected data: blood
pressure, blood glucose, lipid profile. Psychometric test: Hospital
Anxiety and Depression Scale (HADS). QoL was assessed with SF36.
Statistics performed with STATA13.
Results 54 patients enrolled (27 females). Sixteen patients
(30.2%) were positive for anxiety symptoms, ten (18.9%) for depres-
sive symptoms and five (9.4%) for anxiety-depressive symptoms.
The perceived QoL was precarious in twelve subjects (22.2%): eight
(15.9%) had low score (≤ 42) at “Mental Component Summary”
(MCS) subscale, three (5.7%) at the “Mental Health” item and one
patient (1.9%) at the “Vitality” one. At the multiple regression
analysis, depressive (OR = 28.63; P = 0.01) and anxiety-depressive
symptoms (OR = 11.16; P = 0.02) were associated with MCS.
Conclusions The association emerging from the present study
between depressive/anxiety symptoms and the MCS component of
SF36 is consistent with available literature. Study design and small
sample size do not allow to generalize results, that need further
studies to be confirmed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0624
Prevalence, incidence and
comparative meta-analysis of
all-cause and specific-cause
cardiovascular disease in patients
with serious mental illness
M. Solmi ∗, N. Veronese , B. Beatrice , R. Stella ,
S. Paolo , G. Davide , E. Collantoni , G. Pigato , A. Favaro ,
B. Stubbs , A.F. Carvalho , D. Vacampfort ,
C.U. Correll
1 University of Padua, Neuroscience Department, Padua, Italy
2 Institute for clinical Research and Education in Medicine,
Neuroscience Department, Padua, Italy
3 ULSS 17, Mental Health Department, Padua, Italy
4 University of Padua, Department of Medicine, Padua, Italy
5 ULSS 10, Mental Health Department, Portogruaro, Italy
6 South London and Maudsley NHS Foundation Trust, Physiotherapy
Department, London, United Kingdom
7 King’s College London, Health Service and Population Research
Department- Institute of Psychiatry, Psychology and Neuroscience,
London, United Kingdom
8 Faculty of Medicine, Federal University of Ceará, Departmend of
Clinical Medicine and Translational Psychiatry Research Group,
Fortaleza, Brazil
9 KU Leuven, Department of Rehabilitation Sciences, Leuven, Belgium
10 KU Leuven, University Psychiatric Center KU Leuven, Leuven,
Belgium
11 The Zucker Hillside Hospital, Psychiatry Research, New York, USA
12 Albert Einstein College of Medicine, Medicine, New York, USA
13 The Feinstein Institute for Medical Research, Research, New York,
USA
14 Hofstra Northwell School of Medicine, Medicine, New York, USA
∗ Corresponding author.
Patients with severe mental illness (SMI) have been described at
higher risk of cardiovascular disease (CVD). The aimof this systema-
tic reviewandmeta-analysis was to quantify prevalence, incidence,
cross-sectional association and longitudinal increased risk of coro-
nary heart disease (CHD), stroke, transient ischemic attack and
cerebrovascular disease (CBVD), heart failure (HF), peripheral vas-
cular disease (PVD), death due to CVD, and any CVD in patients
with SMI. We included 92 studies, with a total population of
3,371,461 patients (BD = 241,226, MDD = 476,102, SCZ = 1,721,586,
SMI = 932,547) and 113,925,577 controls. Pooled prevalence of
any CVD in SMI was 9.9% (95% CI = 7.4–13.3) (33 studies, 360,144
patients). Compared to controls, after adjusting for a median of 7
confounders, SMI was associated with higher risk of CVD in cross-
sectional studies, OR:1.53 (95% CI = 1.27–1.83) (11 studies), with
CHD OR: 1.51 (95% CI = 1.47–1.55) (5 studies), with CBVD OR: 1.42
(95% CI = 1.21–1.66) (6 studies), and tended to be associatedwithHF
OR: 1.28 (95% CI = 0.99–1.65) (4 studies). Cumulative incidence was
3.6 CVD events in a median follow-up period of 8.4 years (range:
1.76–30). After considering a median of 6 confounders, SMI was
associated with higher longitudinal risk of CVD in longitudinal stu-
dies HR: 1.78 (95% CI = 1.6, 1.98) (31 studies), of CHD: HR: 1.54 (95%
CI 1.30–1.82) (18 studies), of CBVD HR: 1.64 (95% CI 1.26–2.14) (11
studies), of HF HR:2.10 (95% CI 1.64–2.70) (2 studies), of PVD, unad-
justed RR: 3.11 (95% CI 2.46–3.91) (3 studies), of death due to CVD,
HR 1.85 (95% CI 1.53–2.24) (16 studies). In this meta-analysis, the